Experts explain why access to specialty cancer care, open dialogue, and patient education are essential to building trust and making informed treatment decisions.
|Articles|March 19, 2020
COA to Present Virtual Conference Due to Coronavirus
Author(s)Mary Caffrey
“These are times of unprecedented and unimaginable challenges for our health care system."
Advertisement
The Community Oncology Alliance (COA) will present its annual Community Oncology Conference in a virtual format April 23-24, 2020, to join global efforts to stop the spread of COVID-19 (coronavirus).
“These are times of unprecedented and unimaginable challenges for our health care system,” board members said in a letter today. “We have made the obvious decision to cancel the in-person conference.”
The letter said updates on
Advertisement
Related to this article
An intraoperative indocyanine green (ICG) fluorescence imaging protocol in sarcoma surgery detected 14 of 15 positive margins vs 4 of 15 for surgeons, though its specificity was 41.7% vs 88.9%.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Biomarker-driven care is advancing in mantle cell lymphoma, though cost and infrastructure limit access in community oncology, according to a review.
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
AI quantitative CT (UCLA QILD, Brainomix e-Lung) predicts FVC decline and drug response in PPF, strengthening biomarkers beyond spirometry in INBUILD.
Delphi consensus guides dermatology on spotting CTCL vs atopic dermatitis before/after dupilumab, using biopsy plus T-cell clonality testing and safer treatment switches.
Advertisement
Advertisement
Trending on AJMC
1
A New Mechanism for DME in the BRUNELLO Trial: Donald J. D’Amico, MD
2
Using Complement Inhibitors in GA Comes With Pros and Cons
3
Pairing VYD2311 With mRNA COVID-19 Vaccines: Michael Mina, MD, PhD
4
New Mechanism of DME Treatment Highlights Clinical Trial Updates
5